Rapport Therapeutics, a clinical-stage biotech focused on developing RAP-219 for focal onset seizures, reported continued advancement in its Phase 3 clinical program as of June 2026. The company benefits from a strategic collaboration with Tenacia for commercialization rights in Greater China, ensuring geographic market access while maintaining focus on pivotal trials. Solid cash reserves of approximately $63.6 million and a robust current ratio provide financial flexibility amid typical clinical-stage burn. Despite promising developments, residual risk remains around trial enrollment rates, data readouts, and regulatory approvals.